Top

Current Neurology and Neuroscience Reports

Published in:

Open Access 01-08-2021 | Alzheimer's Disease | Dementia (K.S. Marder, Section Editor)

Critical Appraisal of Amyloid Lowering Agents in AD

Authors: Boris Decourt, Fadel Boumelhem, Evans D. Pope III, Jiong Shi, Zoltan Mari, Marwan Noel Sabbagh

Published in: Current Neurology and Neuroscience Reports | Issue 8/2021

Abstract

Purpose of Review

According to the amyloid cascade hypothesis, removing amyloid beta (Aβ) should cure Alzheimer’s disease (AD). In the past three decades, many agents have been tested to try to lower Aβ production, prevent Aβ aggregation, and dissolve Aβ deposits. However, the paucity in definitive preventative or curative properties of these agents in clinical trials has resulted in more avant-garde approaches to therapeutic investigations. Immunotherapy has become an area of focus for research on disease-modifying therapies for neurodegenerative diseases. In this review, we highlight the current clinical development landscape of monoclonal antibody (mAb) therapies that target Aβ plaque formation and removal in AD.

Recent Findings

Multiple potential disease-modifying therapeutics for AD are in active development. Targeting Aβ with mAbs has the potential to treat various stages of AD: prodromal, prodromal to mild, mild, and mild to moderate. Monoclonal antibodies discussed here include aducanumab, lecanemab, solanezumab, crenezumab, donanemab, and gantenerumab.

Summary

The final decision by the FDA regarding the approval of aducanumab will offer valuable insight into the trajectory of drug development for mAbs in AD and other neurodegenerative diseases. Future directions for improving the treatment of AD will include more inquiry into the efficacy of mAbs as disease-modifying agents that specifically target Aβ peptides and/or multimers. In addition, a more robust trial design for AD immunotherapy agents should improve outcomes such that objective measures of clinical efficacy will eventually lead to higher chances of drug approval.

2020 Alzheimer’s disease facts and figures. Alzheimer’s Dement. John Wiley and Sons Inc.; 2020;16:391–460; https://doi.org/10.1002/alz.12068

Todd S, Barr S, Roberts M, Passmore AP. Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry. 2013;28:1109–24. https://doi.org/10.1002/gps.3946.CrossRefPubMed

Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. Cold Spring Harb Perspect Med; 2011;1:a006189–a006189; https://doi.org/10.1101/cshperspect.a006189

Bloom GS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol [Internet]. American Med Assoc. 2014;71:505–8. https://doi.org/10.1001/jamaneurol.2013.5847.CrossRef

Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci Nat Pub Group. 2012;15:349–57. https://doi.org/10.1038/nn.3028.CrossRef

Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW. Functional amyloid formation within mammalian tissue. In: Weissman J, editor. PLoS Biol, vol. 4: Public Library of Science; 2006. p. 0100–7. https://doi.org/10.1371/journal.pbio.0040006.

Love S, Miners S, Palmer J, Chalmers K, Kehoe P. Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. Front Biosci. (Landmark Ed). 2009;14:4778–92. https://doi.org/10.2741/3567.CrossRef

Lu J-X, Qiang W, Yau W-M, Schwieters CD, Meredith SC, Tycko R. Molecular structure of β-amyloid fibrils in Alzheimer’s disease brain tissue. Cell. 2013;154:1257–68. https://doi.org/10.1016/j.cell.2013.08.035.CrossRefPubMed

Thal DR, Rüb U, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology Lippincott Williams and Wilkins. 2002;58:1791–800. https://doi.org/10.1212/WNL.58.12.1791.CrossRefPubMed

10.

Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer’s disease. Nat Neurosci Nature Publishing Group. 2014;17:304–11. https://doi.org/10.1038/nn.3606.CrossRefPubMed

11.

Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol Springer-Verlag. 1991;82:239–59. https://doi.org/10.1007/BF00308809.CrossRefPubMed

12.

Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, et al. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell Elsevier. 2011;144:67–78. https://doi.org/10.1016/j.cell.2010.11.050.CrossRefPubMed

13.

Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (80- ). American Association for the Advancement of Science. 2003;300:486–9. https://doi.org/10.1126/science.1079469.CrossRefPubMed

14.

Guo JL, Lee VMY. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med Nature Publishing Group. 2014;20:130–8. https://doi.org/10.1038/nm.3457.CrossRefPubMedPubMedCentral

15.

Chuang E, Hori AM, Hesketh CD, Shorter J. Amyloid assembly and disassembly. J Cell Sci Company of Biologists Ltd. 2018;131:189928. https://doi.org/10.1242/jcs.189928.CrossRef

16.

He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L, et al. Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med Nature Publishing Group. 2018;24:29–38. https://doi.org/10.1038/nm.4443.CrossRefPubMed

17.

Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid Alzheimer’s disease. Science (80- ). American Association for the Advancement of Science. 1992;256:184–5. https://doi.org/10.1126/science.1566067.CrossRefPubMed

18.

Dickson TC, Vickers JC. The morphological phenotype of β-amyloid plaques and associated neuritic changes in Alzheimer’s disease. Neurosci Pergamon. 2001;105:99–107. https://doi.org/10.1016/S0306-4522(01)00169-5.CrossRef

19.

Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ AAAS. 2006. p. re1. https://doi.org/10.1126/sageke.2006.6.re1.

20.

Ikeda S, Allsop D, Glenner GG. Morphology and distribution of plaque and related deposits in the brains of Alzheimer’s disease and control cases. An immunohistochemical study using amyloid β-protein antibody. Lab Investig. 1989;60:113–22.PubMed

21.

Michno W, Nyström S, Wehrli P, Lashley T, Brinkmalm G, Guerard L, et al. Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1-40 deposition underlies plaque polymorphism in progressing Alzheimer’s disease pathology. J Biol Chem. 2019;294:6719–32. https://doi.org/10.1074/jbc.RA118.006604.CrossRefPubMedPubMedCentral

22.

Strozyk D, Blennow K, White LR, Launer LJ. CSF Aß 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology Lippincott Williams and Wilkins. 2003;60:652–6. https://doi.org/10.1212/01.WNL.0000046581.81650.D0.CrossRefPubMed

23.

Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta;42 in humans. Ann Neurol. 2006;59:512–9. https://doi.org/10.1002/ana.20730.CrossRefPubMed

24.

Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–44. https://doi.org/10.1038/nrneurol.2010.4.CrossRefPubMed

25.

Burnouf S, Gorsky MK, Dols J, Grönke S, Partridge L. Aβ43 is neurotoxic and primes aggregation of Aβ40 in vivo. Acta Neuropathol Springer Verlag. 2015;130:35–47. https://doi.org/10.1007/s00401-015-1419-y.CrossRefPubMedPubMedCentral

26.

Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, et al. Potent amyloidogenicity and pathogenicity of Aβ 243. Nat Neurosci Nature Publishing Group. 2011;14:1023–32. https://doi.org/10.1038/nn.2858.CrossRefPubMed

27.

Seither KM, McMahon HA, Singh N, Wang H, Cushman-Nick M, Montalvo GL, et al. Specific aromatic foldamers potently inhibit spontaneous and seeded Aβ42 and Aβ43 fibril assembly. Biochem J Portland Press Ltd. 2014;464:85–98. https://doi.org/10.1042/BJ20131609.CrossRef

28.

Polanco JC, Li C, Bodea LG, Martinez-Marmol R, Meunier FA, Götz J. Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies. Nat Rev Neurol Nature Publishing Group. 2018;14:22–40. https://doi.org/10.1038/nrneurol.2017.162.CrossRefPubMed

29.

Thal DR, Walter J, Saido TC, Fändrich M. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease. Acta Neuropathol. Springer Verlag; 2015. p. 167–182; https://doi.org/10.1007/s00401-014-1375-y

30.

Imbimbo BP, Watling M. Investigational BACE inhibitors for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs Taylor Francis Ltd. 2019;28:967–75. https://doi.org/10.1080/13543784.2019.1683160.CrossRef

31.

Coimbra JRM, Marques DFF, Baptista SJ, Pereira CMF, Moreira PI, Dinis TCP, et al. Highlights in BACE1 inhibitors for Alzheimer’s disease treatment. Front Chem. Frontiers Media S A. 2018;6:1–10. https://doi.org/10.3389/fchem.2018.00178.CrossRef

32.

Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, et al. Safety and tolerability of the γ-secretase inhibitor Avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012;69:1430–40. https://doi.org/10.1001/archneurol.2012.2194.CrossRefPubMed

33.

Coric V, Salloway S, Van Dyck CH, Dubois B, Andreasen N, Brody M, et al. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol American Medical Association. 2015;72:1324–33. https://doi.org/10.1001/jamaneurol.2015.0607.CrossRefPubMed

34.

Penninkilampi R, Brothers HM, Eslick GD. Pharmacological agents targeting γ-secretase increase risk of cancer and cognitive decline in Alzheimer’s disease patients: a systematic review and meta-analysis. J Alzheimers Dis. IOS Press. 2016;53:1395–404. https://doi.org/10.3233/JAD-160275.CrossRefPubMed

35.

Bursavich MG, Harrison BA, Blain JF. Gamma secretase modulators: new Alzheimer’s drugs on the horizon? J Med Chem American Chemical Society. 2016;59:7389–409. https://doi.org/10.1021/acs.jmedchem.5b01960.CrossRefPubMed

36.

Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology Lippincott Williams and Wilkins. 2004;62:66–71. https://doi.org/10.1212/WNL.62.1.66.CrossRefPubMed

37.

Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA - J Am Med Assoc. American Medical Association. 2009;302:2557–64. https://doi.org/10.1001/jama.2009.1866.CrossRef

38.

Meyer P-F, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan M-É, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner J, for the PREVENT-AD research group INTREPAD: a randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology. Lippincott Williams and Wilkins; 2019;92:e2070–2080; https://doi.org/10.1212/WNL.0000000000007232

39.

Sampson EL, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer’s dementia. Cochrane Database Syst Rev John Wiley and Sons Ltd. 2014;2014:CD005380. https://doi.org/10.1002/14651858.CD005380.pub5.CrossRef

40.

Bush AI, Tanzi RE. Therapeutics for Alzheimer’s disease based on the metal hypothesis. Neurotherapeutics. 2008;5:421–32. https://doi.org/10.1016/j.nurt.2008.05.001.CrossRefPubMedPubMedCentral

41.

Crouch PJ, Savva MS, Hung LW, Donnelly PS, Mot AI, Parker SJ, et al. The Alzheimer’s therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity. J Neurochem. 2011;119:220–30. https://doi.org/10.1111/j.1471-4159.2011.07402.x.CrossRefPubMed

42.

Adlard PA, Bica L, White AR, Nurjono M, Filiz G, Crouch PJ, Donnelly PS, Cappai R, Finkelstein DI, Bush AI Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer’s disease. PLoS One PLoS One; 2011;6:e17669; https://doi.org/10.1371/journal.pone.0017669

43.

Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol Lancet Publishing Group. 2008;7:779–86. https://doi.org/10.1016/S1474-4422(08)70167-4.CrossRefPubMed

44.

Salehi B, Mishra A, Nigam M, Sener B, Kilic M, Sharifi-Rad M, et al. Resveratrol: a double-edged sword in health benefits. Biomedicines. MDPI AG. 2018;6:91. https://doi.org/10.3390/biomedicines6030091.CrossRefPubMedCentral

45.

Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int Pergamon. 2009;54:111–8. https://doi.org/10.1016/j.neuint.2008.10.008.CrossRef

46.

47.

Zilliox LA, Chadrasekaran K, Kwan JY, Russell JW. Diabetes and cognitive impairment. Curr Diab Rep Current Medicine Group LLC 1. 2016;16:87. https://doi.org/10.1007/s11892-016-0775-x.CrossRefPubMedPubMedCentral

48.

Zhang C, Griciuc A, Hudry E, Wan Y, Quinti L, Ward J, et al. Cromolyn reduces levels of the Alzheimer’s disease-associated amyloid β-protein by promoting microglial phagocytosis. Sci Rep Nature Publishing Group. 2018;8:1144. https://doi.org/10.1038/s41598-018-19641-2.CrossRefPubMedPubMedCentral

49.

Jaturapatporn D, Isaac MGEKN, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev Wiley. 2012:CD006378. https://doi.org/10.1002/14651858.CD006378.pub2.

50.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guldo T, et al. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature Nature Publishing Group. 1999;400:173–7. https://doi.org/10.1038/22124.CrossRefPubMed

51.

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet Elsevier. 2008;372:216–23. https://doi.org/10.1016/S0140-6736(08)61075-2.CrossRefPubMed

52.

Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018;8:1–16. https://doi.org/10.1038/s41598-018-24501-0.CrossRef

53.

Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol Springer US. 2019;15:73–88. https://doi.org/10.1038/s41582-018-0116-6.CrossRefPubMed

54.

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature Nature Publishing Group. 2016;537:50–6. https://doi.org/10.1038/nature19323.CrossRefPubMed

55.

Kastanenka KV, Bussiere T, Shakerdge N, Qian F, Weinreb PH, Rhodes K, et al. Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice. J Neurosci Society for Neuroscience. 2016;36:12549–58. https://doi.org/10.1523/JNEUROSCI.2080-16.2016.CrossRefPubMedPubMedCentral

56.

Ferrero J, Williams L, Stella H, Leitermann K, Mikulskis A, O’Gorman J, et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv Elsevier Inc. 2016;2:169–76. https://doi.org/10.1016/j.trci.2016.06.002.CrossRef

57.•

Haeberlein SB, von Hehn C, Tian Y, Chalkias S, Muralidharan KK, Chen T, et al. Emerge and engage topline results: phase 3 studies of aducanumab in early Alzheimer’s disease. Alzheimers Dement. Wiley; 2020;16; https://doi.org/10.1002/alz.047259.Results from EMERGE and ENGAGE offered conflicting data that has led some researchers to question and oppose the potential FDA approval aducanumab for treatment of AD.

58.

Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen. Alzheimers Dement. 2019;2020:1–6. https://doi.org/10.1002/alz.12213.CrossRef

59.

Fillit H, Green A. Aducanumab and the FDA — where are we now? Nat Rev Neurol Springer US. 2021;17:129–30. https://doi.org/10.1038/s41582-020-00454-9.CrossRefPubMed

60.

Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, et al. Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimers Res Ther BioMed Central Ltd.; 2016;8; https://doi.org/10.1186/s13195-016-0181-2

61.

Tucker S, Möller C, Tegerstedt K, Lord A, Laudon H, Sjödahl J, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe Mice. J Alzheimers Dis IOS Press. 2015;43:575–88. https://doi.org/10.3233/JAD-140741.CrossRefPubMed

62.

Söllvander S, Nikitidou E, Gallasch L, Zyśk M, Söderberg L, Sehlin D, et al. The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death. J Neuroinflammation. BioMed Central Ltd.; 2018;15; https://doi.org/10.1186/s12974-018-1134-4

63.

Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, Kowalewski T. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J Mol Biol. 2004;335:997–1006. https://doi.org/10.1016/j.jmb.2003.11.019.CrossRefPubMed

64.

DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2001;98:8850–5. https://doi.org/10.1073/pnas.151261398.CrossRefPubMedPubMedCentral

65.

DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science. 2002;295:2264–7. https://doi.org/10.1126/science.1067568.CrossRefPubMed

66.

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–21. https://doi.org/10.1056/nejmoa1312889.CrossRefPubMed

67.

Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378:321–30. https://doi.org/10.1056/nejmoa1705971.CrossRefPubMed

68.••

Klein G, Delmar P, Kerchner GA, Hofmann C, Abi-Saab D, Davis A, et al. Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab. J Prev Alzheimer’s Dis. 2021;8:3–6. https://doi.org/10.14283/jpad.2020.68This study demonstrates potential long-term efficacy of gantenerumab as an amyloid lowering mAb in AD.CrossRef

69.•

Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D, et al. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019;11:101; https://doi.org/10.1186/s13195-019-0559-z. Based on these results, gantenerumab was established as a safe and effective potential AD treatment.

70.

Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci Society for Neuroscience. 2012;32:9677–89. https://doi.org/10.1523/JNEUROSCI.4742-11.2012.CrossRefPubMedPubMedCentral

71.

Zhao J, Nussinov R, Ma B. Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies. J Biol Chem American Society for Biochemistry and Molecular Biology Inc.; 2017;292:18325–43; https://doi.org/10.1074/jbc.M117.801514

72.

Ultsch M, Li B, Maurer T, Mathieu M, Adolfsson O, Muhs A, et al. Structure of crenezumab complex with aβ shows loss of β-hairpin. Sci Rep Nature Publishing Group. 2016;6:1–11. https://doi.org/10.1038/srep39374.CrossRef

73.

Guthrie H, Honig LS, Lin H, Sink KM, Blondeau K, Quartino A, et al. Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer’s disease treated with escalating doses for up to 133 weeks. J Alzheimers Dis. 2020;76:967–79. https://doi.org/10.3233/JAD-200134.CrossRefPubMedPubMedCentral

74.

Cummings JL, Cohen S, Van Dyck CH, Brody M, Curtis C, Cho W, et al. A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90:E1889–97. https://doi.org/10.1212/WNL.0000000000005550.CrossRefPubMedPubMedCentral

75.

Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimers Res Ther Alzheimer’s Research & Therapy;. 2018;10:1–13. https://doi.org/10.1186/s13195-018-0424-5.CrossRef

76.

Yoshida K, Moein A, Bittner T, Ostrowitzki S, Lin H, Honigberg L, et al. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease. Alzheimers Res Ther. 2020;12:1–12. https://doi.org/10.1186/s13195-020-0580-2.CrossRef

77.

Bittner T, Duning T, Rabe C, Clayton D, Quartino A, Bohorquez SS, et al. P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): biomarker results. Clin Neurophysiol Elsevier BV. 2020;131:e194–5. https://doi.org/10.1016/j.clinph.2019.12.038.CrossRef

78.

Irizarry MC, Sims JR, Lowe SL, Nakano M, Hawdon A, Willis BA, et al. O4-08-06: Safety, pharmacokinetics (PK), and florbetapir F-18 positron emission tomography (PET) after multiple dose administration of LY3002813, A β-amyloid plaque-specific antibody, IN Alzheimer’s disease (AD). Alzheimers Dement Wiley. 2016;12:P352–3. https://doi.org/10.1016/j.jalz.2016.06.665.CrossRef

79.••

Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimer’s Dement (New York, N Y). 2021\;7; https://doi.org/10.1002/trc2.12112. Donanemab improved iADRS score and reduced both amyloid plaque level and global tau load in participants with early symptomatic AD.

80.

Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384:1691–704. https://doi.org/10.1056/NEJMoa2100708.CrossRefPubMed

81.

Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis. 2012;28:49–69. https://doi.org/10.3233/JAD-2011-110977.CrossRefPubMed

Title: Critical Appraisal of Amyloid Lowering Agents in AD
Authors: Boris Decourt
Fadel Boumelhem
Evans D. Pope III
Jiong Shi
Zoltan Mari
Marwan Noel Sabbagh
Publication date: 01-08-2021
Publisher: Springer US
Keywords: Alzheimer's Disease
Alzheimer's Disease
Published in: Current Neurology and Neuroscience Reports / Issue 8/2021
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-021-01125-y

At a glance: The STEP trials

Springer Medicine

Critical Appraisal of Amyloid Lowering Agents in AD

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 8/2021

Debunking Myths: Sinus Headache

Approach to Pediatric Intractable Migraine

The History of Amnesia—a Review

Neurologic Manifestations of the Antiphospholipid Syndrome — an Update